Gynäkologie und Geburtshilfe
Offener Zugang
ISSN: 2161-0932
ISSN: 2161-0932
Saulo Molina-Giraldo , Issis judith Villa-Villa , Roberto Zapata , Mauricio Orozco , Nataly VelásquezMuñoz , Diana Alfonso , Wilma Castilla-Puentes , Jose Luis Pérez , Oscar Ordoñez , Oscar Zuluaga , Jesús Andrés Benavides-Serralde , Carol Gisela Rueda-Ordoñez , Armicson Felipe Solano , Dario Santacruz , Juan Pablo Alzate-Granados
Introduction: Preeclampsia is a multisystemic disease of pregnancy. Prevention of the disease has been a concern of health care models and more so of those that include pathology in which there is a compromise of the perinatal maternal outcome. It has been described that ASA (a cyclooxygenase inhibitor with anti-inflammatory and antiplatelet properties) could have an impact on the prevention of this disease. The purpose of this consensus is to summarize the evidence and provide current recommendations on the use of ASA in the prevention of preeclampsia.
Methods: FECOPEN convened a national meeting of experts to create a non-formal consensus based on a review of the literature with the elaboration of a questionnaire with relevant questions to provide current recommendations on the use of ASA for the prevention of preeclampsia.
Results: A questionnaire of 30 questions was prepared. The consensus was reached on 28 of these questions. The daily use of ASA in the prevention of preeclampsia is considered safe and is associated with a low probability of serious maternal or fetal complications, or both, related to its use. Women at risk for preeclampsia are defined based on the presence of one or more high-risk factors (history of preeclampsia, multifetal gestation, renal disease). Current evidence does not support the prophylactic use of ASA in the absence of high-risk factors for preeclampsia. Additionally, its effectiveness is still debated in the prevention of early pregnancy loss, fetal growth restriction, fetal death, or preterm delivery.